Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Zelda Therapeutics is supplying its oil-based cannabis medicine for a government-funded clinical trial
  • The trial will enrol 600 patients who are suffering from advanced forms of cancer
  • Company Managing Director Dr Richard Hopkins said the supply agreement will generate the company’s first revenue from its branded product
  • Zelda’s share price is up nearly three per cent today and trading for 6.9 cents each

Zelda Therapeutics will have its oil-based cannabis medicine used in a government funded a clinical trial for cancer patients.

The CARE NSW trial is looking to enrol 600 people suffering from advanced forms of cancer.

“The focus on studying cannabis as a strategy to potentially alleviate symptoms in advanced cancer patients is very much aligned to our strategic interest in this area,” company Managing Director Dr Richard Hopkins said.

A number of medical companies specialising in cannabis treatments will be supplying products for the clinical trial, of which Zelda is one.

“The commercial supply agreement also represents a significant milestone for our shareholders, as it is expected to generate the Company’s first revenues from Zelda-branded TGA-TG093 compliant products,” Dr Richard added.

The trial is being conducted by the government funded group the Australian Centre for Cannabinoid Clinical and Research Excellence. The group was established to study cannabis’ therapeutic properties for use in Australia.

Following Zelda’s announcement to the market, shares in the company are up nearly three per cent and trading for 6.9 cents each.

ZLD by the numbers
More From The Market Herald
The Market Herald Video

" Antisense Therapeutics (ASX:ANP) shares rise on long COVID-19 study

Antisense Therapeutics (ASX:ANP) announces the initial outcomes of its collaboration to study the neurological aspects of…
The Market Herald Video

" Immuron (ASX:IMC) shifts focus to therapeutic drug candidate

Immuron (ASX:IMC) has deprioritised SARS-COV-2 research to focus on the clinical development of its therapeutic drug…
The Market Herald Video

" Bod Australia (ASX:BOD) awarded US Hemp Authority certificate for CBD extract

Bod Australia (ASX:BOD) has been awarded US Hemp Authority Certification for its exclusive CBD extract and…
The Market Herald Video

" Fisher & Paykel (ASX:FPH) flags softer profits for first half of FY23

Fisher & Paykel Healthcare (ASX:FPH) has forecast weaker revenue and profits for the half-year to the…